BioSpace News Archive

Adlai Nortye Ltd. and Nucleai is pleased to announce the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

Abiomed, part of Johnson & Johnson MedTech1, announced that novel data from seven research studies focused on optimizing outcomes for patients receiving Impella-supported high-risk percutaneous coronary intervention (HRPCI) will be presented at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium taking place in San Francisco between Oct. 24 - 26.

Mission Bio announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium’s inaugural Interlab Study.

Asklepios BioPharmaceutical, Inc. today announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2023 earnings release and conference call.

Apollomics Inc., announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress 2023, being held in Madrid, Spain from October 20-24, 2023.

Noul Co., Ltd., an Artificial Intelligence based blood and cancer diagnostic platform company, unveiled the results of a clinical study conducted by miLab™ in two African countries.

Magnus Medical, Inc. announced that the American Medical Association has issued new Category III Current Procedural Terminology codes for targeted, accelerated intermittent theta burst stimulation for depression, encompassing Magnus’ SAINT™ targeted treatment.

Aligos Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $92 million, before deducting placement agent fees and other expenses, to advance its portfolio of drug candidates.

Ambrx Biopharma, Inc., or Ambrx, (NASDAQ: AMAM), today announced that in biomarker unselected patients ARX517 monotherapy demonstrated a strong antibody-drug conjugate (ADC) safety profile at all doses tested with promising early efficacy signals that included PSA50 declines, ctDNA reductions, and RECIST v1.1 tumor response.